

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-6. (cancelled)

7. (currently amended) A fusion polypeptide protein specifically inhibiting the translation of a target polynucleotide of interest, comprising: SEQ ID NO 5.

~~a peptide inhibitor of the translation of proteins, said peptide inhibitor having a length up to 250 amino acids and comprising an amino acid sequence possessing at least 85% identity with the amino acid sequence SEQ ID N° 1, and~~

~~an RNA binding protein consisting of MS2CP, wherein said peptide inhibitor is fused with said RNA binding protein, said peptide inhibitor fused with said RNA binding protein is one of SEQ ID N° 5 and SEQ ID N° 6.~~

8-36. (cancelled)

37. (previously presented) A pharmaceutical composition comprising a fusion polypeptide according to claim 7.

38-40. (cancelled)

41. (currently amended) A fusion polypeptide protein specifically inhibiting the translation of a target polynucleotide of interest, consisting of SEQ ID NO 5. ~~ef-one~~
~~ef-SEQ ID N° 5 and SEQ ID N° 6.~~

42. (previously presented) A pharmaceutical composition comprising a fusion polypeptide according to claim 41.